Andere talen Repare Therapeutics Inc.

Aandelen

RPTX

US7602731025

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 26-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
3,2 ^USD	+1,59%		+1,59%	-56,16%

28/02	Repare Therapeutics Inc. Rapporteert winstresultaten voor het volledige jaar dat eindigde op 31 december 2023	CI
28/02	Repare Therapeutics Inc. Rapporteert winstresultaten voor het volledige jaar dat eindigde op 31 december 2023	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Repare Therapeutics Appoints Steven H. Stein, M.D. to its Board of Directors	26/04
Repare Therapeutics Inc. (RPTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings	21/03
Repare Therapeutics Inc. (RPTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings	15/03
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Repare Therapeutics Inc. - RPTX	12/03
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Repare Therapeutics Inc. - RPTX	03/03
Repare Therapeutics to Participate in Two Upcoming Investor Conferences	29/02
Repare Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/02
Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results	28/02
Repare Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/02
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Repare Therapeutics Inc. - RPTX	24/02
Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Repare Therapeutics Inc. (RPTX)	17/02
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Repare Therapeutics Inc. - RPTX	16/02
Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-1664	15/02
Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-1664	15/02
Repare Therapeutics to Regain Global Rights to Oncology Therapy Camonsertib After Termination of Collaboration With Roche	13/02
Repare Therapeutics to Regain Global Rights to Camonsertib	12/02
Repare Therapeutics Announces Achievement of $40 Million Roche Clinical Milestone Payment	25/01
Repare Therapeutics Provides Corporate Update and Highlights Anticipated Key 2024 Milestones	08/01
Repare Therapeutics to Collaborate With Debiopharm on Potential Cancer Therapy	05/01
Repare Therapeutics and Debiopharm Partner to Explore the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition in Cancer	04/01

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Repare Therapeutics Inc.

Aandelen

RPTX

US7602731025

Andere talen

Filters